Skip Navigation

Christina I. Herold, MD

Medical Oncology

Make an Appointment


  • Physician
  • Instructor in Medicine, Harvard Medical School


Clinical Interests

  • Breast cancer

Diseases Treated

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3800 (follow-up)
  • Office Phone Number617-632-3800
  • Fax617-632-1930

Board Certification:

  • Internal Medicine, 2006
  • Medical Oncology, 2009


  • Duke University Medical Center, Hematology/Oncology


  • Hospital of the University of Pennsylvania, Internal Medicine

Medical School:

  • Harvard Medical School


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions


Mamtani A, Gonzalez JJ, Neo D, Slanetz PJ, Houlihan MJ, Herold CI, Recht A, Hacker MR, Sharma R. Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical Outcomes. Ann Surg Oncol. 2016 Oct; 23(10):3371-8.
View in: PubMed

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
View in: PubMed

Bychkovsky BL, Ferreyra ME, Strasser-Weippl K, Herold CI, de Lima Lopes G, Dizon DS, Schmeler KM, Del Carmen M, Randall TC, Nogueira-Rodrigues A, de Carvalho Calabrich AF, St Louis J, Vail CM, Goss PE. Cervical cancer control in Latin America: A call to action. Cancer. 2016 Feb 15; 122(4):502-14.
View in: PubMed

Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J, DeLeonardis K, Sedgwick K, Soltis K, Roa B, Wenstrup RJ, Hartman AR. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015 Jan 01; 121(1):25-33.
View in: PubMed

Herold CI, Anders CK. New targets for triple-negative breast cancer. Oncology (Williston Park). 2013 Sep; 27(9):846-54.
View in: PubMed

Herold CI, Gaughan EM, Lamb CC, Tung NM. Second primary ipsilateral breast cancer with contralateral axillary involvement: a case report and literature review. Clin Breast Cancer. 2011 Dec; 11(6):406-8.
View in: PubMed

Herold CI, Chadaram V, Peterson BL, Marcom PK, Hopkins J, Kimmick GG, Favaro J, Hamilton E, Welch RA, Bacus S, Blackwell KL. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res. 2011 Sep 15; 17(18):6061-70.
View in: PubMed

Herold CI, Gasparetto C, Arepally GM. Lenalidomide-Associated ITP. Case Rep Hematol. 2011; 2011:638020.
View in: PubMed

Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011 Aug; 9(8):997-1007.
View in: PubMed

Herold CI, Djulbegovic B, Hozo I, Lyman GH. Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. Breast Cancer Res Treat. 2010 Jun; 121(3):771-6.
View in: PubMed

Herold CI, Marcom PK. Primary systemic therapy in breast cancer: past lessons and new approaches. Cancer Invest. 2008 Dec; 26(10):1052-9.
View in: PubMed

Herold CI, Blackwell KL. Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. Clin Breast Cancer. 2008 Feb; 8(1):50-64.
View in: PubMed

Herold CI, Blackwell KL. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. Breast. 2008 Jan; 17 Suppl 1:S15-24.
View in: PubMed